Notably, inhibitors targeting pathways such as mTOR, PI3K, and the cell cycle/DNA replication machinery may act downstream of TONSL, TIMELESS, RFC3, and RAD51. These pathways have been widely recognized for their crucial roles in tumor progression (41–43). This evidence concerns the gene RFC3 and neoplasm.